Thirona

Nijmegen, the Netherlands  All Netherlands companies → Founded 2014
Imaging AI Specialist Specialty-Focused AI
Pulmonology Radiology
Oncology AI Radiology & Imaging AI
Series B and grants — €7.5 million (approximately $8 million USD)

Products

LungQ Software
Thirona Corporation
Oncology AI
LungQ by Thirona is an AI-powered software for comprehensive analysis of thoracic CT scans, providing quantitative insights for the diagnosis, treatment planning, and follow-up of various lung diseases. It offers advanced segmentation and quantification of lung structures, including airways, vessels, and parenchyma, and is FDA-cleared for clinical use.

See all 1 product →

About Thirona

Thirona is an innovative Dutch MedTech company specializing in artificial intelligence (AI) for medical image analysis, aiming to bridge the gap between academic advancements and clinical application. For physicians, Thirona offers cutting-edge software solutions that provide precise and efficient quantification of medical images, primarily focusing on thoracic CT scans (LungQ™), chest X-rays (CAD4TB), and retinal images (RetCAD™). These AI-powered tools assist healthcare professionals in the detection, evaluation, and treatment planning of various lung diseases, including COPD, asthma, lung cancer, cystic fibrosis, and pulmonary hypertension, as well as ophthalmic conditions like diabetic retinopathy.

The company’s technology empowers earlier and more accurate diagnoses, contributes to personalized treatment strategies, and streamlines workflows for clinicians. Thirona’s LungQ™ platform, for instance, provides reproducible CT values for pulmonary tissue, essential for quantitative support in diagnosis, patient selection for treatment, and follow-up examinations. Thirona also supports pharmaceutical companies and research institutions by accelerating imaging-based respiratory clinical trials and advancing minimally invasive interventions, with its solutions validated in numerous peer-reviewed publications.

Thirona operates under ISO 13485 certification and is compliant with the EU’s Medical Device Regulation (MDR), ensuring high standards of quality and regulatory adherence for its clinically proven AI software, which is utilized in hundreds of hospitals worldwide.

Focus Areas

AI-powered lung image analysis precision medicine for lung diseases drug development pulmonary interventions COPD Bronchiectasis Disease Severe Asthma Cystic Fibrosis lung cancer thoracic CT scans chest X-rays

Business Intelligence

Key InvestorsEuropean Innovation Council (EIC), Borski Fund, HERAN Partners, MannKind Corporation
PartnershipsBlackford, Voiant, VIDA Diagnostics, Avicenna.AI, Radboud University Medical Center (RUMC), ScreenPoint Medical
AcquisitionsDivestment of Thirona Retina B.V. to Revenio Group's subsidiary Icare Finland Oy in August 2024
TechnologyLungQ (modular AI technology for thoracic CT analysis, including advanced segmentation and quantification capabilities, deep learning models), CAD4TB (AI for chest X-rays)
FDA ClearancesMultiple (at least 4 versions of LungQ: v3.0.0, v3.1.0, v3.y.z, v4) cleared products (estimated)

What Physicians Need to Know

AI-Powered Lung Image Analysis
Thirona specializes in advanced AI-powered analysis of thoracic CT scans, offering precise, sensitive, and objective quantification of pulmonary structural abnormalities. Their LungQu00ae platform provides a comprehensive structural profile of the lung, including airways, blood vessels, and parenchyma, with granular regional insights.
Precision Medicine & Drug Development
The company's technology enables precise patient phenotyping and personalized treatment strategies for lung diseases. It significantly supports pharmaceutical drug development by providing objective biomarkers and sensitive assessment of treatment response in clinical trials for both common and rare respiratory conditions.
Pulmonary Interventions
Thirona's solutions assist in interventional pulmonology by guiding bronchoscopic navigation, biopsy preparation, and live navigation, particularly for lung cancer. It also supports tissue-sparing surgical decision-making by offering a clearer understanding of lung anatomy.
Disease Expertise
Their AI algorithms are specifically designed and validated for a wide range of lung diseases, including COPD, Bronchiectasis Disease, Severe Asthma, Cystic Fibrosis, and lung cancer, addressing the heterogeneity and complexity of these conditions.
Key Differentiators
Thirona stands out with its extensively validated AI technology (over 180 scientific publications), FDA-cleared LungQ 3.0.0 for automatic segmentation of pulmonary segments, and over 20 years of research experience in chest CT analysis. Their focus on objective, reproducible quantitative metrics surpasses subjective visual interpretation.
Technology Stack
The core technology relies on advanced deep learning and AI algorithms for high-fidelity segmentation and quantification. This includes sophisticated algorithms for identifying parenchymal, bronchial, and vascular anatomy down to subsegments, as well as image registration for multi-modal and longitudinal analysis.
Physician Tip

For physicians, Thirona's AI-powered LungQu00ae software offers objective, reproducible, and highly accurate insights into lung anatomy and disease progression, moving beyond subjective visual assessments. This leads to enhanced diagnostic accuracy, earlier detection of subtle abnormalities, and more precise patient phenotyping for truly personalized treatment planning. The automated analysis significantly reduces the time and expertise required for complex image interpretation, such as in Cystic Fibrosis, allowing for faster clinical decision-making and improved patient monitoring. Furthermore, for interventional pulmonologists, the software acts as a 'map' for lung anatomy, providing critical 3D visualization and real-time guidance for bronchoscopic procedures, which can increase diagnostic yield and enable more tissue-sparing interventions.

Thirona's LungQu00ae software is designed for flexible integration, available via AI marketplaces or distribution platforms, and can also function as a stand-alone web-based solution. They actively pursue strategic partnerships, such as with VIDA Diagnostics and Avicenna.AI, to expand their capabilities and facilitate seamless access to their advanced AI-powered lung analyses within existing clinical trial services and diagnostic workflows.

Products by Thirona

1 product in the directory

LungQ Software
Thirona Corporation
Oncology AI
LungQ by Thirona is an AI-powered software for comprehensive analysis of thoracic CT scans, providing quantitative insights for the diagnosis, treatment planning, and follow-up of various lung diseases. It offers advanced segmentation and quantification of lung structures, including airways, vessels, and parenchyma, and is FDA-cleared for clinical use.

What the Web Says

Thirona is an innovative Dutch MedTech company specializing in AI for medical image analysis, particularly for CT scans of the lungs and retinal fundus images. Their products, like LungQu2122 and RetCADu2122, aim to improve patient outcomes, streamline workflows for clinicians, and support research in areas such as COPD, asthma, lung cancer, and diabetic retinopathy. The company has received FDA clearance for its LungQu2122 software and is actively involved in international clinical trials and research collaborations. While specific reviews for Thirona on platforms like G2, Glassdoor, Capterra, and Reddit were not directly found, general sentiment around similar healthcare IT and AI-powered solutions on these platforms tends to be positive regarding efficiency and support, with some concerns about initial setup and user interface.

Overall: Mixed

Strengths

  • AI-powered for high-precision quantitative analysis of medical images, especially lung CT scans.
  • Products like LungQu2122 aim to improve patient outcomes and streamline clinician workflows.
  • LungQu2122 software has received FDA clearance, indicating regulatory approval and reliability.
  • Actively supports international clinical trials and research collaborations.
  • Focuses on bridging the gap between academic theory and clinical application with intuitive products.
  • Strong emphasis on scientific excellence and collaboration within a research-driven environment.

Limitations

  • Specific product and employer reviews for Thirona were not readily available on major review platforms like G2, Glassdoor, Capterra, or Reddit.
  • General challenges in similar software include potential for complex initial setup and configuration.
  • Some AI-powered platforms can have a learning curve for users not accustomed to the technology.
  • Lack of direct reviews makes it difficult to assess specific user experience or employer sentiment for Thirona.
  • Potential for extra costs if content usage exceeds agreed limits in some platforms.

Based on reviews from: G2, Glassdoor, Capterra, Google Search (healthcare IT reviewers, company information), Reddit

Last updated: 2026-07-19

Videos

News, demos, and interviews about Thirona.

Loading videos...

Videos load interactively. If none appear, search YouTube for Thirona →

View all on YouTube

Press & Coverage

Borski Fund
Thirona Raises u20ac7,5 Million New Financing to Accelerate the Adoption of its Breakthrough Innovations for Precision Medicine
Thirona secured u20ac7.5 million in new financing, including a u20ac5 million investment from HERAN Partners and Borski Fund, and a u20ac2.5 million grant from the European Innovation Council (EIC), to accelerate the adoption of its AI-powered innovations for precision medicine in lung diseases.
2023-09
Thirona
Thirona Receives FDA Clearance for LungQu00ae 4 Software, Expanding AI-Powered Capabilities in Lung Image Analysis for the U.S. Market
Thirona announced that its LungQu00ae 4 AI-powered CT analysis software received 510(k) clearance from the U.S. Food and Drug Administration (FDA), expanding its capabilities in peripheral airway segmentation, chronic perfusion defect estimation, and post-treatment detection of endobronchial implants.
2025-10
Business Wire
Thirona receives FDA 510(k) Clearance for LungQ v3.0.0 Software to Power AI Analysis of Chest CT Images
Thirona received FDA 510(k) clearance for LungQu2122 (v3.0.0), its AI-based clinical software for advanced analysis of thoracic CT images, making new features widely available for use in U.S. hospitals.
2024-01
ITN Online
Thirona Announces Partnerships to Enhance AI-based Lung Image Analysis
Following FDA approval for its LungQ (v3.0.0) software, Thirona announced multiple partnerships, including with Blackford and Voiant, to integrate its AI-based lung image analysis into broader healthcare platforms and accelerate respiratory clinical trials.
2024-06
Thirona
Thirona and SEPAR Launch an Educational Project for Pulmonologists on AI-Based Quantitative CT Analysis in Severe Asthma
Thirona and SEPAR have launched an educational project aimed at pulmonologists, focusing on the application of AI-based quantitative CT analysis in severe asthma.
2026-06
Thirona
Thirona spins out the Retina business to pursue long-term growth plans
Thirona announced the spin-out of its Retina division into Thirona Retina BV, effective January 1, 2023, to allow both entities to pursue long-term growth plans in their specialized fields of lung and retinal image analysis.
2023-01
BioWorld
Thirona secures $2.73M in funding from EIC for AI-based lung platform
Thirona BV was awarded $2.73 million in funding from the European Innovation Council (EIC) to accelerate the development of its AI-based lung platform for analyzing chest CT imaging.
2023-07
The Lancet Respiratory Medicine
Effect of elexacaftoru2013tezacaftoru2013ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study
A multicentre prospective observational study published in The Lancet Respiratory Medicine investigated the effect of elexacaftoru2013tezacaftoru2013ivacaftor on bronchial dilatations in adolescents with cystic fibrosis.
2025-10

Frequently Asked Questions

Thirona's flagship product for lung image analysis is LungQu00ae, a modular AI-powered platform designed for comprehensive assessment of lung anatomy and diseased regions from thoracic CT scans. LungQu00ae addresses a wide range of lung conditions including COPD, Bronchiectasis Disease, Severe Asthma, Cystic Fibrosis, lung cancer, and interstitial lung disease (ILD), providing quantitative insights for diagnosis, treatment planning, and monitoring.
Thirona's LungQu00ae technology provides high-precision anatomical segmentation and sensitive quantitative analysis, offering an objective view of disease distribution and changes over time. This enables precise patient phenotyping, identification of small airway disease, and non-invasive evaluation of vascular abnormalities, supporting personalized treatment strategies and interventional care.
Thirona's LungQu00ae software has received U.S. Food and Drug Administration (FDA) 510(k) clearance for multiple versions, including LungQ v3.0.0 and LungQ 4, making its features available in the United States. The software is also approved for clinical use in Europe, the UK, and Australia, and the company operates under a certified Quality Management System (ISO 13485) and is compliant with EU MDR and GDPR.
Yes, Thirona's LungQu00ae platform is designed for AI-powered analysis of thoracic CT scans, supporting efficient workflows in diagnosis and treatment planning. While LungQ focuses on CT, Thirona has also developed AI solutions for chest X-rays, such as CAD4TB, demonstrating their capability to integrate into diverse imaging modalities and clinical contexts.
Thirona partners with pharmaceutical companies and CROs to advance drug development by providing sensitive and accurate quantitative CT analysis for imaging-based respiratory clinical trials. Their LungQu00ae metrics serve as imaging endpoints to precisely evaluate treatment efficacy and disease progression, facilitating personalized medicine and accelerating clinical trial pathways.
Thirona offers support through direct contact channels for general and product inquiries. They actively pursue partnerships with research institutions, academic hospitals, and MedTech companies to enhance AI-based lung analysis and integrate their solutions into broader healthcare platforms, such as with Blackford and VIDA Diagnostics.
Founded in 2014, Thirona has grown into a recognized expert in AI-powered medical image analysis, with its LungQu00ae platform installed in over 1,200 hospitals worldwide. The company secured u20ac7.5 Million in financing in 2023, including investments from HERAN Partners and Borski Fund, and a grant from the European Innovation Council, indicating strong financial backing and a commitment to accelerating innovation.

Investors

Who's funded Thirona.

Related Companies

Clarista is a healthcare AI company that focuses on building a “trust layer” for enterprise AI, particularly within regulated industries like healthcare and financial services. The company’s platform aims to address the challenges of data fragmentation, governance, and compliance that often hinder the successful implementation of AI projects in large organizations. Clarista’s technology unifies structured […]

HelloBooks.ai is an AI-powered accounting software company that aims to automate and simplify financial management for small businesses, freelancers, and accounting professionals. The platform utilizes generative AI to handle repetitive bookkeeping tasks such as transaction categorization, receipt capture, bank reconciliation, and report generation. It is designed to reduce manual data entry and improve accuracy, allowing […]

Vero, also known as Vero.ai, is an artificial intelligence company specifically designed to augment clinical workflows and improve patient care within the healthcare sector. Their primary focus is on leveraging AI to streamline administrative tasks, enhance diagnostic accuracy, and personalize treatment plans. By automating routine processes, Vero aims to free up healthcare professionals’ time, allowing […]

Ant Group, a global digital technology provider and operator of Alipay, has significantly expanded its focus into healthcare AI. The company recently upgraded its physician platform, Haodf for Doctor, into ‘AQ for Doctor,’ an AI-powered workstation designed to support physicians across various stages of clinical practice, including online consultations, patient management, clinical decision support, and […]

e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]

PayZen is a healthcare AI company dedicated to solving the healthcare affordability crisis for both patients and providers. The company’s AI-powered platform offers personalized, interest-free, and fee-free patient financing solutions, enabling patients to manage their medical bills through affordable payment plans tailored to their unique ability to pay. This approach aims to increase access to […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.